ArticleJapanese journal of cancer and oncology research2025
Chondrosarcoma: Adjuvant Therapeutic Effects of the ASPH Small Molecule Inhibitor, SMI-1182, With Doxorubicin.
Article in Japanese journal of cancer and oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chondrosarcoma (CS) is the most common adult malignant bone tumor. Its poor prognosis is due to chemotherapy resistance and high rates of post-treatment recurrence. The finding that CSs express abundant Aspartyl-Asparaginyl-Β-Hydroxylase (ASPH), which drives invasive tumor growth via Notch pathway activation, provides a new opportunity for treatment in combination with standard Doxorubicin (DOX) chemotherapy. We hypothesized that the small-molecule inhibitor SMI-1182, which targets the catalytic domain of ASPH, could enhance the chemotherapeutic effects of DOX by further reducing CS cell viability, motility, and invasive growth. Human CS-1 and CDS11 conventional chondrosarcoma cell lines were treated with broad dose ranges of DOX, SMI-1182, or DOX+SMI-1182 to measure their separate and combined effects on cell viability, toxicity, motility, and invasive growth. Mechanistic studies included assessments of genes and proteins pertinent to ASPH expression and Notch signaling. Treatment with DOX or SMI-1182 caused dose-dependent CS-1 and CDS11 cell loss and cytotoxicity. SMI-1182, with or without DOX, significantly reduced directional motility and invasive growth relative to vehicle. Combined treatments with DOX and SM-1182 had synergistic cytotoxic and anti-invasive growth effects linked to reduced expression of ASPH immunoreactivity, Notch transcription factors, and insulin receptor substrate, type I, which positively regulates both ASPH and Notch. Dual treatment with DOX and SMI-1182 could potentially improve disease-free survival with CS by simultaneous targeting of multiple upstream mediators of aggressive malignant tumor behavior.
Indexed as
Identifiers
42491925PMC13378441What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.